Clinical trialNCT05570253RecruitingPhase 2Interventional

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

SponsorMemorial Sloan Kettering Cancer CenterEnrollment55Breast CancerMetastatic Triple-Negative Breast Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Sherry Shen, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Baptist Alliance - Mci (data Collection Only)
Miami, Florida, United States
Recruiting
Emory University (data Collection Only)
Atlanta, Georgia, United States
Recruiting
Memorial Sloan Kettering Basking Ridge (all Protocol Activities)
Basking Ridge, New Jersey, United States
Recruiting
Hackensack Meridian Health
Hackensack, New Jersey, United States
Recruiting
Memorial Sloan Kettering Monmouth (all Protocol Activities)
Middletown, New Jersey, United States
Recruiting
Memorial Sloan Kettering Bergen (all Protocol Activities)
Montvale, New Jersey, United States
Recruiting
Memorial Sloan Kettering Suffolk - Commack (all Protocol Activities)
Commack, New York, United States
Recruiting
Memorial Sloan Kettering Westchester (all Protocol Activities)
Harrison, New York, United States
Recruiting
Memorial Sloan Kettering Cancer Center (all Protocol Activities)
New York, New York, United States
Recruiting
Memorial Sloan Kettering Nassau (all Protocol Activities)
Uniondale, New York, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Eribulin →SDX-7320

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 3 Oct 2022
Primary completion: 31 Oct 2027
Completion: 31 Oct 2027
Last update posted: 5 Aug 2026
Registered enrollment: 55
Registry id: NCT05570253

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.